Page last updated: 2024-12-04

racemethionine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Racemethionine: A preparation of METHIONINE that includes a mixture of D-methionine and L-methionine isomers. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID876
CHEMBL ID274119
CHEBI ID16811
SCHEMBL ID4225
MeSH IDM0013577

Synonyms (161)

Synonym
Z00115
alpha-amino-gamma-methylmercaptobutyric acid
2-amino-4-(methylthio)butanoic acid
racemethionine
2-amino-4-(methylsulfanyl)butanoic acid
CHEBI:16811 ,
nsc45689
l(-)-amino-.gamma.-methylthiobutyric acid
l-.alpha.-amino-.gamma.-methylmercaptobutyric acid
.gamma.-methylthio-.alpha.-aminobutyric acid
2-amino-4-methylthiobutanoic acid
butyric acid, 2-amino-4-(methylthio)-
wln: qvyz2s1 -l
methionine,l-
l-.gamma.-methylthio-.alpha.-aminobutyric acid
nsc22946 ,
dl-methioninum
methionine, amorphous
(+-)-methionine
nsc 9241
dl-2-amino-4-(methylthio)-butyric acid
alpha-amino-gamma-methylmercaptobutyric acid (van)
alpha-amino-gamma-(methylthio)butyric acid
racemethionine [usan]
einecs 200-432-1
pedameth
ccris 3717
fema no. 3301
methionine dl-
ai3-18475
d,l-methionine
mertionin
meonine
.alpha.-amino-.gamma.-methylmercaptobutyric acid
urimeth
(.+-.)-methionine
nsc-9241
dl-2-amino-4-(methylthio)butyric acid
nsc9241
cynaron
banthionine
dyprin
dl-methionine ,
acimetion
lobamine
metione
neston
dl-2-amino-4-(methylthio)butanoic acid
2-amino-4-methylsulfanyl-butanoic acid
methilonin
D04983
racemethionine (usan)
dl-methionine (jan)
padameth (tn)
nsc118113
methionine, dl-
nsc-118113
nsc-522406
nsc522406
33807-07-7
C01733
59-51-8
2-amino-4-(methylthio)butyric acid
dl-methionine, bioreagent, suitable for cell culture, suitable for insect cell culture, >=99%
dl-methionine, >=99%
dl-methionine, 99%, fcc, fg
NCGC00159431-02
NCGC00159431-03
C6115881-E914-4EA8-A21A-DCBF67783824
AKOS000118924
CHEMBL274119
methionine dl-form
FT-0690213
FT-0693483
M0463
h-dl-met-oh
2-amino-4-methylsulfanylbutanoic acid
STK802463
NCGC00159431-04
unii-73jwt2k6t3
racemethionine [usan:usp:nf]
73jwt2k6t3 ,
tox21_111663
dtxcid50821
cas-59-51-8
dtxsid9020821 ,
(+/-)-methionine
BBL009323
cas_84815
bdbm86195
cas_6137
nsc_84815
nsc_6137
S9344
FT-0671134
FT-0625489
FT-0625547
AM20100433
AB00373904-02
dl-2-amino-4-methylthiobutanoic acid
dl-methionine [fcc]
dl-methionine [who-ip]
dl-methionine [who-dd]
dl-methioninum [who-ip latin]
racemethionine [usp-rs]
dl-methionine [ep monograph]
methionine dl-form [mi]
dl-methionine [ep impurity]
dl-methionine [mart.]
dl-methionine [jan]
d,l-methionine [fhfi]
AKOS016050523
SCHEMBL4225
SY004418
amurex
2-amino-4-(methylmercapto)butyric acid
petameth
dl-ch3sch2ch2ch(nh2)cooh
(.+/-.)-methionine
metion
h3csch2ch2ch(nh2)cooh
dl-met
2-amino-4-(methylthio) butyric acid
J-300193
Q-201029
7005-18-7
dl-methionine;
mfcd00063096
(+/-)-2-amino-4-(methylmercapto)butyric acid
FT-0699633
FT-0698675
F0001-1544
SR-01000944495-1
sr-01000944495
dl-methionine, saj special grade, >=99.0%
racemethionine, united states pharmacopeia (usp) reference standard
dl-methionine, >=99.0% (nt)
dl-methionine, european pharmacopoeia (ep) reference standard
dl-methionine, vetec(tm) reagent grade, 98%
dl-methionine; (2rs)-2-amino-4-(methylsulfanyl)butanoic acid
racemethionine, usan
fema 3301
Z57127440
dl-methionine (racemethionine)
FT-0771524
dl-methionine-3,3,4,4-d4
DB13972
DS-16180
Q180341
CS-0008889
CCG-266195
dl-methionin
D72471
met248
HY-N0325
2-amino-4-methylsulfanyl-butyric acid
EN300-17984
padameth
methio-form
racemethionine (usp-rs)
racemethionine (usan:usp:nf)

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The aim of the present study was to determine the efficacy of methionine restriction with rMETase and a low-methionine diet combined with first-line neo-adjuvant chemotherapy, in a patient with metastatic ILC of the breast."( Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction.
Aoki, Y; Hamada, K; Han, Q; Hoffman, RM; Hozumi, C; Kubota, Y; Masaki, N; Obara, K; Tsunoda, T, 2022
)
0.72
"Combination therapy of doxorubicin and cyclophosphamide followed by docetaxel combined with methionine restriction led to a remarkable complete response that is expected in fewer than 10% of patients with ILC of the breast treated with neo-adjuvant chemotherapy alone."( Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction.
Aoki, Y; Hamada, K; Han, Q; Hoffman, RM; Hozumi, C; Kubota, Y; Masaki, N; Obara, K; Tsunoda, T, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" The relative bioavailability of L-Met to DL-Met was 160% based on a multilinear regression analysis of weight gain."( Effects of supplemental L-methionine on growth performance and redox status of turkey poults compared with the use of DL-methionine.
Ferket, PR; Kim, SW; Malheiros, RD; Park, I; Pasquetti, T, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"A dose-response experiment was conducted to investigate the effects of excess DL-methionine (DLM) and L-methionine (LM) on growth response of starter Pekin ducks from 7 to 21 days of age."( Effects of excess DL- and L-methionine on growth performance of starter Pekin ducks.
Hou, SS; Huang, W; Tang, J; Xie, M; Xue, JJ; Zhang, Q, 2018
)
0.48
"D-met significantly reduced PTS for impulse noise (100 mg [2, 6, 14 and 20 kHz]; 200 mg [2, 14 and 20 kHz]) and steady-state noise (all dosing groups, time parameters and tested frequencies)."( D-methionine administered as late as 36 hours post-noise exposure rescues from permanent threshold shift and dose-dependently increases serum antioxidant levels.
Buhnerkempe, M; Campbell, KCM; Cosenza, N; Fox, DJ; Meech, R; Qin, J; Rybak, L, 2023
)
0.91
" Restricted cubic splines were plotted to evaluate the dose-response relationship between dietary OCM-related nutrient intake and the risk of PE."( One-carbon metabolism-related nutrients intake is associated with lower risk of preeclampsia in pregnant women: a matched case-control study.
Bo, Y; Cao, Y; Dou, W; Duan, D; Fu, W; Liu, Y; Lyu, Q; Ma, S; Zeng, F; Zhao, X, 2022
)
0.72
" Rumen NALM dosing led to a linear increase in plasma Met concentration."( Plasma methionine appearance and residual potential of supplemented N-acetyl-L-methionine through ruminal or abomasal infusion in dairy cows.
Eun, JS; Fagundes, MA; Hall, JO,
)
0.13
" The development of time-stable dosage forms of radiopharmaceuticals is the key to their successful implementation in clinical practice."( Radiolysis-Associated Decrease in Radiochemical Purity of
Larenkov, A; Mitrofanov, I; Pavlenko, E; Rakhimov, M, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
Daphnia magna metaboliteA Daphnia metabolite produced by the species Daphnia magna.
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
sulfur-containing amino acid
alpha-amino acidAn amino acid in which the amino group is located on the carbon atom at the position alpha to the carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Amino acid transport defects (IEMs)925
Vitamin B12 disorders1313

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency15.08900.000221.22318,912.5098AID743035
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (218)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (3.67)24.3611
2020's210 (96.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.98 (24.57)
Research Supply Index5.50 (2.92)
Research Growth Index6.59 (4.65)
Search Engine Demand Index38.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (7.02%)5.53%
Reviews13 (5.70%)6.00%
Case Studies4 (1.75%)4.05%
Observational0 (0.00%)0.25%
Other195 (85.53%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]